Table 1.
Clinical course of the patient.
| March, 2019 Pretreatment with prednisolone |
August, 2019 Posttreatment with prednisolone (after 3 months) |
September 2021 Pretreatment with mepolizumab |
November 2021 Posttreatment with mepolizumab (after 3 months) Pretreatment with dupilumab |
Feburary, 2022 Posttreatment with dupilumab (after 3 months) |
|
|---|---|---|---|---|---|
| FEV1 (mL) | 1720 | 1900 | 1760 | 1720 | 1900 |
| %FEV1 (%) | 115.4 | 131.9 | 123.9 | 121.1 | 134.7 |
| FEV1/FVC (%) | 80.4 | 85.2 | 80.4 | 82.69 | 84.1 |
| FeNO (ppb) | 59 | 15 | 18 | 13 | 13 |
| Eosinophils (cells/μL) | 1137 | 70 | 958 | 91 | 96 |
| IgE (U/L) | 241 | 755 | 929 | 4110 | 1660 |
| ACT | 13 | 24 | 18 | 13 | 25 |
FEV1: Forced expiratory volume in 1 sec, FVC: Forced vital capacity, FeNO: Fractional exhaled nitric oxide, ACT: Asthma control test.